AIDS Malignancy Consortium (AMC)

艾滋病恶性肿瘤协会 (AMC)

• 批准号: 10259756
• 负责人: Joseph A. Sparano
• 金额: $ 2217.42万
• 依托单位: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-08-29 至 2025-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10259756
• 关键词: AIDS Malignancy Consortium; AIDS clinical trial group; AIDS related cancer; Accountability; Acquired Immunodeficiency Syndrome; Address; Africa; Africa South of the Sahara; Americas; Anus; Area; Cancer Biology; Cancer Control; Cancer Survivor; Caring; Clinical; Clinical Trials; Clinical Trials Cooperative Group; Clinical Trials Network; Collaborations; Communities; Community Outreach; Complex; Development; Diagnosis; Epidemic; Fostering; Funding; Generations; Goals; HIV; Health Professional; Human Papilloma Virus-Related Malignant Neoplasm; Incidence; International; Intervention; Intervention Studies; Kaposi Sarcoma; Laboratories; Laboratory Research; Laboratory Scientists; Laboratory Study; Latin America; Lead; Leadership; Lesion; Lymphoma; Malignant - descriptor; Malignant Neoplasms; Malignant neoplasm of anus; Mission; Morbidity - disease rate; National Cancer Institute; Patients; Phase; Phase I/II Trial; Physicians; Population; Practice Guidelines; Precancerous Conditions; Precision therapeutics; Prevention; Prevention approach; Public Health; Publications; Randomized; Reporting; Research; Research Personnel; Role; Scientist; Site; Squamous intraepithelial lesion; Strategic Planning; Structure; Supervision; Surveys; United States; Virus Diseases; Vision; Work; antiretroviral therapy; burden of illness; cancer prevention; career; cohesion; design; improved; insight; low and middle-income countries; mortality; next generation; novel diagnostics; novel therapeutics; operation; personalized immunotherapy; phase III trial; premalignant; prevent; preventive intervention; programs; recruit; research clinical testing; routine screening; screening; standard of care; survivorship; translational scientist; vision aid; AIDS Malignancy Consortium; AIDS clinical trial group; AIDS related cancer; Accountability; Acquired Immunodeficiency Syndrome; Address; Africa; Africa South of the Sahara; Americas; Anus; Area; Cancer Biology; Cancer Control; Cancer Survivor; Caring; Clinical; Clinical Trials; Clinical Trials Cooperative Group; Clinical Trials Network; Collaborations; Communities; Community Outreach; Complex; Development; Diagnosis; Epidemic; Fostering; Funding; Generations; Goals; HIV; Health Professional; Human Papilloma Virus-Related Malignant Neoplasm; Incidence; International; Intervention; Intervention Studies; Kaposi Sarcoma; Laboratories; Laboratory Research; Laboratory Scientists; Laboratory Study; Latin America; Lead; Leadership; Lesion; Lymphoma; Malignant - descriptor; Malignant Neoplasms; Malignant neoplasm of anus; Mission; Morbidity - disease rate; National Cancer Institute; Patients; Phase; Phase I/II Trial; Physicians; Population; Practice Guidelines; Precancerous Conditions; Precision therapeutics; Prevention; Prevention approach; Public Health; Publications; Randomized; Reporting; Research; Research Personnel; Role; Scientist; Site; Squamous intraepithelial lesion; Strategic Planning; Structure; Supervision; Surveys; United States; Virus Diseases; Vision; Work; antiretroviral therapy; burden of illness; cancer prevention; career; cohesion; design; improved; insight; low and middle-income countries; mortality; next generation; novel diagnostics; novel therapeutics; operation; personalized immunotherapy; phase III trial; premalignant; prevent; preventive intervention; programs; recruit; research clinical testing; routine screening; screening; standard of care; survivorship; translational scientist; vision aid

PROJECT SUMMARY/ABSTRACT The AIDS Malignancy Consortium (AMC) was established in 1995 and has been at the forefront of the clinical evaluation of interventions for the treatment and prevention of malignancies in people living with the human immunodeficiency virus (PLWH). AMC also studies the biology of cancers and precancerous lesions in PLWH in the context of its clinical trials, providing new insights on further improving the treatment and prevention of cancer. The AMC has conducted over 100 clinical trials, surveys and laboratory studies involving over 8700 patients with HIV- associated cancers and precancerous lesions since its inception, including application of precision therapeutics and immunotherapy, impacting the standard of care for PLWH and cancer. AMC has established a network of 42 core clinical trial sites in the United States, Africa, and Latin America uniquely qualified carry out its mission, created a network of translational scientists and their research laboratories that support AMC clinical trials, and developed a career enhancement program that has fostered a new generation of physicians and scientists with unique expertise in HIV-associated cancers. Expansion of AMC to clinical trials sites in sub- Saharan Africa and Latin America is designed to address regions of the world where the epidemic of HIV and cancer has grown substantially, thereby amplifying the potential clinical impact of its work to a global scale. AMC has also actively engaged PLWH and cancer survivors in its scientific planning and community outreach in order to identify the needs of the community, and disseminate information about AMC and its completed and ongoing research. The participation of many of the key clinicians and clinical researchers, laboratory scientists, and community representatives has made AMC the principal clinical trials group in the world dedicated to improving the treatment and prevention of cancers in this population. We propose to continue and expand our domestic and international clinical trials work in these areas, including the ANCHOR trial; ANCHOR is a large randomized study investigating the role of routine screening for and treatment of high-grade anal squamous intraepithelial lesions, with the goal of preventing development of invasive anal cancer and the morbidity and mortality associated with its diagnosis and treatment, thereby establishing new diagnostic and therapeutic paradigm.

项目摘要/摘要 艾滋病恶性财团（AMC）成立于1995年，一直处于最前沿 对治疗和预防恶性肿瘤干预措施的临床评估 患有人类免疫缺陷病毒（PLWH）的人。 AMC还研究了 在临床试验的背景下，PLWH中的癌症和癌性病变，提供新的 关于进一步改善癌症治疗和预防的见解。 AMC进行了 超过100次临床试验，调查和实验室研究，涉及8700多名HIV患者 自成立以来相关的癌症和癌前病变，包括应用 精确治疗和免疫疗法，影响PLWH和 癌症。 AMC已在美国，非洲建立了一个由42个核心临床试验地点组成的网络， 拉丁美洲独特地执行其使命，建立了翻译网络 支持AMC临床试验并开发的科学家及其研究实验室 职业增强计划促进了新一代的医生和科学家 具有与HIV相关的癌症方面的独特专业知识。将AMC扩展到子临床试验地点 撒哈拉非洲和拉丁美洲旨在解决世界各地 艾滋病毒和癌症的流行已经大大增长，从而扩大了潜在的临床 其工作对全球规模的影响。 AMC还积极参与PLWH和癌症幸存者 在其科学规划和社区宣传中，以确定社区的需求， 并传播有关AMC及其完成且正在进行的研究的信息。这 许多关键临床医生和临床研究人员，实验室科学家和参与 社区代表使AMC成为世界上的主要临床试验小组 致力于改善该人群中癌症的治疗和预防。我们建议 为了继续并扩大我们在这些领域的国内和国际临床试验工作， 包括锚定试验；锚是一项大型随机研究，研究了 常规筛查和治疗高级肛门鳞状上皮内病变，并与 防止侵入性肛门癌以及发病率和死亡率的目标 与诊断和治疗相关，从而建立新的诊断和 治疗范式。